Provided By GlobeNewswire
Last update: Nov 24, 2025
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB
Read more at globenewswire.comNASDAQ:CRVO (11/26/2025, 1:29:53 PM)
9.68
+0.05 (+0.52%)
Find more stocks in the Stock Screener


